SpacePharma has developed SPACTORY, the first drug factory in Space. It is a miniaturized, fully automated microgravity space factory operated remotely from Earth. This technology utilizes the unique conditions of microgravity to produce more stable and purer drugs. SPACTORY’s modular design allows for efficient and flexible production of various pharmaceuticals, ensuring higher-quality formulations and increased therapeutic potency.
SpacePharma’s innovation is set to revolutionize cancer treatments with more targeted and efficient therapies, reducing side effects and improving patient outcomes. For pharmaceutical companies, it offers cost-effective production and enhanced product quality. This technology aligns with key EU initiatives, promoting health, economic growth, and innovation. By 2030, SpacePharma aims to achieve significant revenue, job creation, and global expansion, positioning Europe as a leader in space pharmaceutical technology.
Thanks to their innovation, SpacePharma has received blended finance from the highly competitive EIC Accelerator March 2024 cut-off. They secured over €2 million in grant funding and €7.5 million in equity. This funding will help accelerate the development and scaling of their space-based drug manufacturing technology.
